Anzeige
❌
Mehr »
Donnerstag, 19.11.2026 - Börsentäglich über 12.000 News
Folge dem Geld: Methan im Fokus der COP31!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
CS

WKN: A2AM00 | ISIN: SE0008241558 | Ticker: 4A1
Frankfurt
18.11.26 | 20:15
0,000 Euro
-98,15 % -0,005
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERENO SCIENTIFIC AB Chart 1 Jahr
5-Tage-Chart
CERENO SCIENTIFIC AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0050,04518.11.

Aktuelle News zur CERENO SCIENTIFIC Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrXFRA 4A1: WIEDERAUFNAHME/RESUMPTION159FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME...
► Artikel lesen
04.11.Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q3 2026177Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
03.11.XFRA 4A1: AUSSETZUNG/SUSPENSION229DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCERENO SCIENTIFIC...
► Artikel lesen
03.11.Suspension of Trading in Cereno Scientific AB at FNSE5832026-11-03T12:17:09ZSuspensionAt Trading Venue FNSEDue to Non Disclosure Of Inside Information About The Issuer Or Financial InstrumentOngoing: TrueComments: Nasdaq Stockholm has, to the extent applicable...
► Artikel lesen
02.11.Cereno Scientific AB: Cereno Scientific Sees Strong Investigator Engagement as EPIMODE Phase IIb Trial Advances199Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
08.10.Cereno Scientific AB: Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results293Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides an update...
► Artikel lesen
25.09.Cereno Scientific AB: Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD687Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced positive...
► Artikel lesen
26.08.Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q2 2026653Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
CERENO SCIENTIFIC Aktie jetzt für 0€ handeln
13.08.Cereno Scientific AB: Cereno Scientific Activates First Clinical Site in Global Phase IIb EPIMODE Trial of CS1 in PAH, Enabling Patient Recruitment410Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for rare cardiovascular and pulmonary diseases, today announced that the first...
► Artikel lesen
08.07.Cereno Scientific AB: Cereno Scientific Confirms that Members of Management and Chair of Board have Acquired Shares for a Total of Over 1.5 MSEK398Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced, that...
► Artikel lesen
26.06.Cereno Scientific AB: Cereno Scientific Reports EAP Analyses with CS1 in PAH: Majority of Completing Patients Achieved Stable or Improved Clinical Status over 12 Months419Cereno Scientific (Nasdaq First North: CRNO B), a biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today reported further analyses...
► Artikel lesen
17.06.Cereno Scientific AB: Cereno Scientific AB (publ) publishes report from the Annual General Meeting 2026581Today, June 17, 2026, Cereno Scientific AB (publ) held its Annual General Meeting at the MAQS Advokatbyrå's premises at Masthamnsgatan 13 in Gothenburg, Sweden. Chairperson of the Annual General Meeting...
► Artikel lesen
27.05.Cereno Scientific AB: Cereno Scientific Publishes Interim Report for Q1 20261.306Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
11.05.Cereno Scientific AB: Cereno Scientific Enters Collaboration with PHA Europe & Global to Advance Patient-centered Drug Development in Pulmonary Hypertension591Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced a collaboration...
► Artikel lesen
04.04.Cereno Scientific AB: Cereno Scientific Highlights Strategic Value of Meeting Primary Endpoint of Safety and Tolerability of 12-month CS1 Data in PAH1.032Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today provides additional...
► Artikel lesen
31.03.Cereno Scientific Reports Favorable Safety and Tolerability after 12 Months of CS1 Treatment in PAH from the Expanded Access Program580GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare...
► Artikel lesen
23.03.Cereno Scientific - Inflection points coming into view1.058Cereno Scientific's FY25 results mark a strategically productive period, with multiple value inflection points coming into focus in FY26. With the Phase IIb start for lead asset CS1 expected in Q226...
► Artikel lesen
19.03.Cereno Scientific - capital markets day highlights (Video)1.006In this video, we go behind the scenes at Cereno Scientific's capital markets day, speaking with key stakeholders, including company leadership, industry experts and patients living with pulmonary arterial...
► Artikel lesen
17.03.Cereno Scientific Receives Approval to Initiate FDA-aligned Phase I Pharmacokinetic Study of CS014 Supporting Phase II Development in PH-ILD967GOTHENBURG, Sweden, March 17, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare...
► Artikel lesen
27.02.Cereno Scientific AB: Cereno Scientific Publishes Year-end Report for 2025 (January 1 - December 31, 2025)1.055Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that...
► Artikel lesen
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1